- Home
- ADXN vs APVO Comparison
ADXN vs APVO Comparison
Compare ADXN & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- APVO
- Stock Information
- Founded
- ADXN 2002
- APVO 2016
- Country
- ADXN Switzerland
- APVO United States
- Employees
- ADXN N/A
- APVO N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- APVO Health Care
- Exchange
- ADXN Nasdaq
- APVO Nasdaq
- Market Cap
- ADXN 10.1M
- APVO 4.1M
- IPO Year
- ADXN N/A
- APVO N/A
- Fundamental
- Price
- ADXN $9.00
- APVO $2.92
- Analyst Decision
- ADXN Strong Buy
- APVO Strong Buy
- Analyst Count
- ADXN 1
- APVO 1
- Target Price
- ADXN $30.00
- APVO $5,920.00
- AVG Volume (30 Days)
- ADXN 14.3K
- APVO 6.7M
- Earning Date
- ADXN 08-11-2025
- APVO 08-07-2025
- Dividend Yield
- ADXN N/A
- APVO N/A
- EPS Growth
- ADXN N/A
- APVO N/A
- EPS
- ADXN 0.10
- APVO N/A
- Revenue
- ADXN $278,508.00
- APVO N/A
- Revenue This Year
- ADXN $86.57
- APVO N/A
- Revenue Next Year
- ADXN N/A
- APVO N/A
- P/E Ratio
- ADXN $0.75
- APVO N/A
- Revenue Growth
- ADXN N/A
- APVO N/A
- 52 Week Low
- ADXN $6.51
- APVO $2.81
- 52 Week High
- ADXN $13.27
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- ADXN 51.86
- APVO 34.14
- Support Level
- ADXN $8.78
- APVO $2.89
- Resistance Level
- ADXN $9.89
- APVO $3.05
- Average True Range (ATR)
- ADXN 0.54
- APVO 0.19
- MACD
- ADXN -0.05
- APVO 0.22
- Stochastic Oscillator
- ADXN 35.97
- APVO 10.54
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.